Minerva Capital Research Solutions

Aarti Pharmalabs

NSE: AARTIPHARMBSE: 543748
Compare with peers
₹ 879.00▼ 6.9 (−0.78%)28 Oct, 03:29 pm IST
Market cap
₹ 7,421 Cr.
P/E
37.1x
P/B
3.54x
52-week range
585 – 1,002.4
ROE
9%
ROCE
11%
Dividend yield
0.4%
Debt / equity
0.36
Sector
Pharmaceuticals & Biotechnology
Industry
Pharmaceuticals
Listed on
NSE, BSE

About

Aarti Pharmalabs Limited is engaged in the manufacturing of active pharmaceutical ingredients (APIs), advanced intermediates, and xanthine derivatives. The Company also offers comprehensive contract development and manufacturing organization (CDMO) and CMO services for drug substances and new chemical entities (NCE), including their key starting materials (KSM) and regulatory starting materials (RSM), serving various pharmaceutical companies worldwide with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of HPAPIs, corticosteroids, cytotoxic medicines, and oncology products. Its caffeine products include caffeine anhydrous, and caffeine anhydrous (granules). Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. The Company's products are exported to key regulated markets such as the United States (US), the European Union, and Japan.

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Pharmaceuticals: 221 companies →

Aarti Pharmalabs against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)37.1 against a typical 34.3: pricier than most peers (1st = cheapest).122nd of 220
  • Sales growth+38.9% against a typical +15.6% from a year earlier.40th of 197
  • Profit growth+52% against a typical +18.9% from a year earlier.51st of 160
  • Share price, 3 months+28.7% against a typical −0.5%.24th of 200
  • Size₹ 7,420.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).46th of 199

Credit ratings

Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates

High safety

Rated AA- by CRISIL
AA-
DefaultRiskyModerateSafeVery safe
  • No warnings from the agency.
AgencyCurrent ratingOutlookAs of
CRISILCrisil AA-Stable9 Oct 2026
Credit rating actions
RatingDetails
9 Oct 2026
Reaffirmed
Crisil AA-—CRISIL₹ 1,000 Cr.
13 Mar 2026
Rating action
Crisil AA-—CRISIL₹ 700 Cr.

Board meetings

Results dates and other board meetings. Full calendar

Details
28 Oct 2026UpcomingFinancial ResultsTo consider and approve the financial results for the period ended September 30, 2026
7 Aug 2026Financial ResultsTo consider and approve the financial results for the period ended Jun 30, 2026
25 May 2026Financial Results/DividendAARTIPHARM : 25-May-2026 : The Company has informed the Exchange that a Board meeting to be held on May 18, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be held on May 25, 2026, To consider and approve the financial results for the period ended March 31, 2026 and dividend
18 May 2026Financial Results/DividendTo consider and approve the financial results for the period ended March 31, 2026 and dividend
9 Feb 2026Financial Results/DividendAARTI PHARMALABS LIMITED has informed the Exchange about Board Meeting to be held on 09-Feb-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 31, 2025 and Dividend/Other business.
9 Nov 2025Financial ResultsTo consider and approve the unaudited standalone and consolidated financial results for the period ended September 30, 2025
12 Aug 2025Financial ResultsTo consider and approve the unaudited financial results for the period ended Jun 30, 2025

Share price

1Y change +5.76%
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales440449506555458538564386418432583536
Expenses352353388459364409418293344330470400
Operating Profit889611896941291469374102113136
OPM %20%21%23%17%20%24%26%24%18%24%19%25%
Other Income112245−2202148
Interest44556107711131713
Depreciation181919202123232325292830
Profit before tax677496747210111565396382101
Tax %23%29%32%25%24%26%23%24%28%24%25%25%
Net Profit525365555574885028486176
EPS in Rs5.725.827.26.126.038.169.755.463.085.296.748.4

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
—
5 Years
—
3 Years
−2%
TTM
1%
Compounded Profit Growth
10 Years
—
5 Years
—
3 Years
−3%
TTM
−19%
Stock Price CAGR
10 Years
—
5 Years
—
3 Years
32%
TTM
—
Return on Equity
10 Years
—
5 Years
13%
3 Years
12%
TTM
—

Shareholding

Latest: Jun 2026.

Promoters
42.86%
−0.86 pts in a year
FIIs
8.17%
+0.83 pts in a year
DIIs
7.22%
−0.58 pts in a year
Government
0.01%
0 pts in a year
Public
41.74%
+0.62 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 37.1xEPS (12 months) ₹ 23.74Median P/E 26.6x
P/E (times)EPS (₹)

Peers

Listed companies in the same business.

Peer comparison
Aarti Pharmalabs₹ 879.00₹ 7,421 Cr.37.1x3.5x9%—
Sun Pharmaceutical Industries₹ 1,743.00₹ 4,18,194 Cr.38.4x5.6x14.2%19.1%
Divi's Laboratories₹ 8,984.00₹ 2,38,497 Cr.73.3x11.5x16.2%24.3%
Torrent Pharmaceuticals₹ 4,482.00₹ 1,70,475 Cr.72.7x19.2x27.1%15.3%
Cipla₹ 1,337.00₹ 1,08,011 Cr.27.6x3.3x11.8%13.7%
Zydus Lifesciences₹ 1,127.85₹ 1,12,503 Cr.21.2x4.2x19.7%18.5%

Management

Rashesh Chandrakant Gogri
Chairman of the Board
Hetal Gogri Gala
Vice Chairperson of the Board, Managing Director
Rakeshwar Bandichhor
Chief Scientific Officer - Research and Development
Jeevan Bhargav Mondkar
Company Secretary and Compliance Officer

Prices are delayed and for information only. Nothing on this page is investment advice.